医学
免疫组织化学
胶质瘤
放射性配体
谷氨酸羧肽酶Ⅱ
脑转移
活检
病理
转移
癌症研究
前列腺癌
癌症
内科学
受体
作者
Ilanah J. Pruis,Vera van Dis,Sybren L. N. Maas,Rutger K. Balvers,Thierry P. P. van den Bosch,Marcel Segbers,Sophie E. M. Veldhuijzen van Zanten
标识
DOI:10.1007/s00259-025-07338-4
摘要
Abstract Purpose Prostate-specific membrane antigen (PSMA) is a potential target for radioligand therapy (RLT) in neuro-oncology. This study investigates the direct relation between [ 68 Ga]Ga-PSMA-11 uptake on PET and PSMA expression in the tumour micro-environment of high-grade glioma (HGG) and brain metastasis (BM). Methods Twelve patients with HGG (glioblastoma n = 6, oligodendroglioma n = 1), or BM (lung- n = 4, breast cancer n = 1), underwent PET-MRI after intravenous [ 68 Ga]Ga-PSMA-11 injection (1.5 MBq/kg), followed by image-guided biopsy sampling during (re-)resection surgery. Multiple samples (median n = 3/patient, n = 23 HGG/ n = 20 BM) from locations of low and high [ 68 Ga]Ga-PSMA-11 uptake were analysed for PSMA expression in vasculature and non-vascular structures using morphology and immunohistochemistry. Results All patients showed [ 68 Ga]Ga-PSMA-11 uptake in tumour ( SUVmax median, range: 10.5, 4.7–19.8). Strong PSMA expression was found in tumour microvasculature (14/23, 61% in HGG, 13/20, 65% in BM). Tumour cell PSMA expression was found in a subset of HGG (10/23; of which strong in 8/10) and BM (3/20; none of which showed strong expression). Strong PSMA expression was also found on non-malignant glial cells in tumour. PSMA expression in healthy brain control samples was negligible. In HGG, a significant correlation existed between [ 68 Ga]Ga-PSMA-11 uptake and PSMA expression in tumour microvasculature (r = 0.487, P < 0.01), but not tumour cells. Conclusion PSMA expression in brain tumours is predominately vascular, which likely explains why microvascular (rather than tumour cell) PSMA expression correlates with [ 68 Ga]Ga-PSMA-11 uptake in HGG. This neovascular expression is crucial information for future PSMA-based RLT studies, as alpha-emitters may not sufficiently target tumour DNA. NCT05798273; date of registration: 1/9/2020.
科研通智能强力驱动
Strongly Powered by AbleSci AI